ClinicalTrials.gg

Program

efmirenpase alfa

Its studies are mostly in Pseudoxanthoma Elasticum · Calciphylaxis, led by BioMarin Pharmaceutical.

Furthest: phase 3, since Aug 28, 20238 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceutical80 open or runningphase 3since Aug 28, 2023Dec 22, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2020First study: phase 2 study in Hypophosphatemic Rickets, Autosomal Recessive, 1First studyNCT04686175 · 13 enrolled · United States, Canada, France and more
  2. Aug 26, 2021Phase 2 study in Pseudoxanthoma ElasticumNCT05030831 · 10 enrolled · United States, United Kingdom
  3. Jan 26, 2023Phase 1 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT05734196 · 9 enrolled · United States, Spain, United Kingdom
  4. Aug 28, 2023Phase 3 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT06046820 · 27 enrolled · United States, Australia, Canada and more
  5. Feb 21, 2024Phase 1 study in CalciphylaxisNCT06283589 · 11 enrolled · United States
  6. Jun 12, 2024Phase 2 study in Pseudoxanthoma ElasticumNCT06462547 · 22 enrolled · United States, France, Germany and more
  7. Dec 11, 2024Phase 2 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT06739980
  8. Mar 11, 2026Phase 3 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT07473973 · 2 enrolled · Brazil, France, Hungary and more
  9. Oct 1, 2026Phase 3 study terminatedStudy stoppedNCT06046820 · “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program …”
  10. Oct 15, 2026Phase 1 study terminatedStudy stoppedNCT05734196 · “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program …”
  11. Oct 19, 2026Phase 2 study terminatedStudy stoppedNCT06462547 · “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program …”

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07473973Hypophosphatemic Rickets, Autosomal Recessive, 1 · Brazil, France, Hungary and more3TerminatedAug 31, 20262
NCT06739980Hypophosphatemic Rickets, Autosomal Recessive, 12WithdrawnMar 31, 20270
NCT06462547Pseudoxanthoma Elasticum · United States, France, Germany and more2TerminatedSep 30, 202622
NCT06283589Calciphylaxis · United States1CompletedJul 27, 202411
NCT06046820Hypophosphatemic Rickets, Autosomal Recessive, 1 · United States, Australia, Canada and more3TerminatedJan 29, 202627
NCT05734196Hypophosphatemic Rickets, Autosomal Recessive, 1 · United States, Spain, United Kingdom1TerminatedSep 29, 20269
NCT05030831Pseudoxanthoma Elasticum · United States, United Kingdom2CompletedJul 9, 202410
NCT04686175Hypophosphatemic Rickets, Autosomal Recessive, 1 · United States, Canada, France and more2CompletedOct 29, 202413

How it is read

Names in the registry

  • “INZ-701”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.